1 NASDAQ: SCHN Financial Results Fourth Quarter and Fiscal Year 2022 October 24, 2022 Recycling Today for a Sustainable Tomorrow Safe Harbor Statements and information included in this presentation by Schnitzer Steel Industries, Inc. that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Except as noted herein or as the ...

Schnitzer Steel Industries, Inc. (SCHN) Q4 2022 Earnings Conference Call October 24, 2022 11:30 AM ET Company Participants Michael Bennett - Vice President, Investor Relations Tamara Lundgren - Chairman and Chief Executive Officer Stefano Gaggini - Chief Financial Officer Conference Call Participants Emily Chang - Goldman Sachs Operator Good day, and welcome to the Schnitzer Steel's Conference Call, Fourth Quarter 2022 Earnings Release Call and Webcast. At this time, all participants are in a listen-only mo ...

Financial Data and Key Metrics Changes - The company reported record third quarter adjusted earnings per share of $2.59, nearly double the second quarter and 18% higher year-over-year [14] - Adjusted EBITDA for the third quarter was $119 million, representing $105 per ferrous ton, the highest Q3 in the company's history [39] - Operating cash flow was positive at $45 million, with net debt increasing to $306 million primarily due to the acquisition of Encore Recycling [49][50] Business Line Data and Key Metrics Changes - Non-ferrous sales volumes increased sequentially by 37% and year-over-year by 29%, reflecting contributions from Columbus Recycling and Encore Recycling [46] - Finished steel sales volumes rose by 27% sequentially, driven by strong construction demand, with average selling prices up 41% year-over-year [48] - Ferrous sales volumes increased by 5% sequentially but were down 7% year-over-year due to slower export demand [43] Market Data and Key Metrics Changes - Average selling prices for recycled ferrous metals reached historically high levels exceeding $650 per ton at the start of the quarter but fell to $450-$500 per ton by the end [22][23] - Non-residential and infrastructure projects on the West Coast showed strong growth, with total U.S. construction spending rising by almost 13% year-over-year [19] - The company expects robust demand in construction markets to continue, supported by the U.S. Infrastructure Bill [20] Company Strategy and Development Direction - The company is focused on technology investments in advanced metal recovery systems to enhance non-ferrous metal extraction [29] - Strategic priorities include ferrous volume growth, expansion of products and services, and productivity initiatives to offset inflationary pressures [30][31] - The company is well-positioned to benefit from structural trends in EAF steelmaking capacity and decarbonization efforts [59] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds from China's COVID lockdowns and the Russian war in Ukraine but emphasized strong underlying demand trends for recycled metals [27] - The outlook for the fourth quarter includes expectations for increased ferrous and non-ferrous sales volumes year-over-year, with finished steel sales volumes expected to more than double compared to the previous year [53] - The company highlighted its resilience in various market conditions, supported by a diversified sales platform and integrated operations [56] Other Important Information - The company achieved ISO certification for six sites as part of its environmental management system goals [13] - Capital expenditures for fiscal 2022 are expected to be in the range of $130 million to $150 million, focusing on growth projects and environmental-related initiatives [51] Q&A Session Summary Question: Criteria for M&A Evaluation - Management evaluates acquisitions on a through-the-cycle basis, considering historical multiples and operational synergies [68] Question: Strategy for Southeast Region Expansion - The company targets strong industrial activity in the Southeast and seeks to acquire operations that provide operational leverage and synergies [72] Question: Logistics Constraints and Easing - Management noted improvements in container availability and freight costs, attributing some easing to China's slowdown [74]

NASDAQ: SCHN Financial Results Third Quarter Fiscal 2022 June 29, 2022 Recycling Today for a Sustainable Tomorrow Safe Harbor Statements and information included in this presentation by Schnitzer Steel Industries, Inc. that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Except as noted herein or as the context may ot ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended May 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________ to __________ Commission File Number 000-22496 SCHNITZER STEEL INDUSTRIES, INC. (Exact name of registrant as specified in its charter) OREGON ...

Q1 2022 Results P R E S E N T E D B Y : Radius Health, Inc. May 5, 2022 Safe Harbor Any statements made in this presentation relating to future financial or business performance, guidance, conditions, plans, prospects, trends or strategies and other financial or business matters are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the continued commercialization of TYMLOS® (abaloparatide) injection and abaloparatide-SC ex-U.S., ...

Financial Data and Key Metrics Changes - For Q1 2022, the company reported net product revenue of $43 million, a decrease of 5.2% compared to Q1 2021, primarily due to reduced volume shipments and high distributor inventory levels from the previous year [18][19] - Operating expenses were managed effectively, with R&D costs declining by $9 million or 28% year-over-year, while SG&A costs decreased by $4 million or 12% [19][20] - The net loss for Q1 2022 was $18 million, an increase of $3 million from Q1 2021, but adjusted for a regulatory milestone, there was a $7 million improvement [20][21] - The company ended Q1 with $72 million in cash and cash equivalents, reflecting a net cash burn of about $40 million for the quarter [21][22] Business Line Data and Key Metrics Changes - TYMLOS, the core revenue-generating asset, saw a net revenue of $43 million for Q1 2022, with an average active patient number of almost 14,800 monthly, up 4% year-over-year [26][27] - The company is targeting $232 million in net revenue for the year, with approximately 42% expected in the first half [27][28] Market Data and Key Metrics Changes - The company is preparing for the U.S. male osteoporosis market launch, which is expected to have a patient base 10% to 25% larger than the female market [12][28] - The regulatory submission for Abaloparatide in the male indication was submitted in Q1 2022, with expectations for a launch in early Q1 2023 [30][32] Company Strategy and Development Direction - The company is focused on maximizing cash flow generation from TYMLOS and expanding its market presence both in the U.S. and internationally [11][50] - Elacestrant is positioned as a significant asset, with ongoing evaluations and potential market opportunities expanding due to recent failures of competitors [13][36] - The company is also advancing RAD011, with pivotal programs planned for Angelman syndrome and Prader-Willi syndrome, aiming to address significant unmet medical needs [41][44] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the competitive landscape and emphasized the importance of maintaining operational efficiencies while managing cash flow [31][64] - The company remains optimistic about the potential for Elacestrant and RAD011, highlighting the lack of competition in certain therapeutic areas [51][64] Other Important Information - The company has a milestone payment structure in place with Menarini, with potential regulatory and sales milestones totaling $320 million [80] - The company plans to return 100% of capital from Elacestrant to stakeholders, which may include share buybacks, debt repayment, or dividends [80][81] Q&A Session Summary Question: What is the overlap between the male and female osteoporosis prescriber base? - Management indicated a significant overlap in the prescriber base, primarily consisting of endocrinologists and rheumatologists, suggesting minimal changes to the sales structure will be needed [54] Question: How is the company managing operating efficiencies? - Management noted that the process of streamlining operations is ongoing, with a focus on re-engineering parts of the business while maintaining a slight downward trend in total headcount [57] Question: What are the sources of capital for development programs? - Management highlighted the importance of integrated cash flow management and indicated that they are comfortable with the current cash position and potential future milestones [61][64] Question: What is the expected patient share gain for TYMLOS sales guidance? - Management stated that they are targeting a moderate 5% growth year-over-year, focusing on increasing active patient numbers and managing the patient journey effectively [74] Question: What is the status of Elacestrant's competitive landscape? - Management acknowledged the improving competitive landscape and emphasized the significant market opportunity, while also noting that the financial arrangement with Menarini remains unchanged [66][68] Question: What is the expected approval timeline for TYMLOS in Canada? - Management confirmed that they expect a milestone payment upon approval in Canada, with potential launches in multiple international markets anticipated in 2023 [92]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended February 28, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-22496 SCHNITZER STEEL INDUSTRIES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Schnitzer Steel Industries, Inc. (SCHN) Q2 2022 Results Conference Call April 6, 2022 11:30 AM ET Company Participants Michael Bennett - Vice President of Investor Relations Tamara Lundgren - Chairman and Chief Executive Officer Richard Peach - Chief Financial Officer and Chief Strategy Officer Operator Thank you for standing by, and welcome to the Schnitzer Steel Second Quarter 2022 Earnings Release Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation ...

Financial Performance - Adjusted EBITDA reached $75 million, marking the best Q2 in the company's history[21, 24] - Adjusted EPS from continuing operations was $1.38[24] - Adjusted EBITDA per ferrous ton was $70[24, 43] Volume and Sales - Ferrous sales volumes increased year-over-year by 10%, reaching 1,071,000 long tons[21, 24] - Nonferrous sales volumes increased year-over-year by 8%, totaling 147 million pounds[21, 24] - Finished steel sales volumes were 106,000 short tons[24] Strategic Initiatives and Sustainability - The company achieved 100% net carbon-free electricity use in FY21[10, 14] - Scope 1 & 2 emissions are 19% below the FY19 base[10] - The company is targeting a ferrous sales volume of 53 million tons by the end of FY23[33] Market Dynamics - The company's steel mill operated at an average utilization rate of 86% in 2Q22[21, 57] - Twitch now accounts for 14% of total nonferrous volumes in 2Q22[51]